Overview

A Study of MORAb-003 in Patients With Solid Tumor

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

MORAb-003 is intravenously administered to Japanese patients with folate receptor-alpha expressing solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Co., Ltd.

Treatments:

Farletuzumab